Historical evidence and clinical attribution

All 196 historical findings have an explicit disposition and linked current record: 178 revised, 14 retained, 3 unresolved, 1 rejected. The complete ledger retains each original finding, prior status, access depth, limitations and antibody adjudication. This inventory does not complete the wider literature reviews in issues #636 and #638.

Material unresolved cases

MAGEC2, LGALS13 and PLCZ1 enter Other with a sequence-review requirement. Their reviews are accepted as complete at the stated access depth; the interpretations remain unresolved. No new positive normal-protein exclusion is asserted.

Case	Evidence and unresolved question
MAGEC2	Li 2003 reports Purkinje staining with TC-1. The abstract was rechecked; full reagent/control validation was unavailable. A negative bulk profile cannot resolve specificity.
LGALS13	1999 PP13 work reports extra-placental immunoreactivity, while 2009 work supports placental restriction. Adult/fetal anatomy and galectin identity remain unresolved; only abstracts were rechecked.
PLCZ1	Zhu 2003, Methods/Figure 1: qualitative pancreatic NYD-SP27 RNA remains unresolved quantitatively and by isoform. Immunostaining measured CFTR, so the rejected PLCZ1 protein interpretation stays rejected.

The other 178 historical antibody conflicts retain their observations and prior adjudications. Their blanket historical hold is revised by the declared current HPA level/reliability, prior reagent-eligibility and compartment rules, not by a claim that every antibody conflict was experimentally resolved. Current assay decisions remain reproducible and visible in the candidate audit; consumers must not apply a second, private historical IHC classifier.

Product injury and competing peptide explanations

The original neurological report recorded three neurological cases, including two deaths, among nine recipients of the HLA-A*02 MAGE-A3/A9/A12-reactive TCR. The 2021 re-examination challenges the MAGEA12 attribution and supplies EPS8L2 cross-reactivity evidence. Its RNA FISH, peptide assays, HLA immunopeptidomics and cell-line killing experiments support an alternative without proving the initiating patient-brain peptide. Rare MAGEA12 cells and other targets remain possible. Full-text Methods, Results, Figures 1–4, Tables 1–3 and Discussion were reviewed; supplementary experiments were not reanalysed.

Fatal product-specific injury still blocks favorable clinical credit. Unique gene-level causality is unresolved. MAGEA12 remains Unsafe through independent rare Vital-cell RNA evidence, whose limitations remain separate. The HLA-A*01 a3a/titin cardiac cases involve a different receptor and peptide.

Reproducible consequences

Relative to the decision-contract PR: 216 classification changes, 197 sequence-role changes and 704 reason changes. All changes include unchanged categories with changed reasons. The series-wide delta uses the frozen 1.29.0 baseline.

from oncoref import gene_knowledge, cta_selection_audit, tcr_trials
gene_knowledge.historical_dispositions("PLCZ1")
cta_selection_audit.audit().findings("PLCZ1")  # includes rejected/context findings
tcr_trials.events()  # causal_findings retains both peptide hypotheses

Current findings, clinical ledger, and receipt preserve the source and policy boundaries.